홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

퍼헥실린

Perhexiline

HCID 4746
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
35193-73-8
표준 SMILES
C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
InChIKey
CYXKNKQEMFBLER-UHFFFAOYSA-N
분자식
C19H35N
평균 분자량
277.5 g/mol
단동위원소 질량
277.27695012

개요

Perhexiline is a member of piperidines. It has a role as a cardiovascular drug.

이름 및 식별자

우선 이름
Perhexiline
IUPAC
2-(2,2-dicyclohexylethyl)piperidine
현지명
퍼헥실린
영어명
perhexiline
분자식
C19H35N
분자량
277.49

이름 및 동의어

PERHEXILINE2-(2,2-Dicyclohexylethyl)piperidinePerhexilene6621-47-2PerhexilinaPiperidine, 2-(2,2-dicyclohexylethyl)-PerhexilinumDTXSID7023439KU65374X44CHEBI:35553RefChem:860305DTXCID603439
이름 더 보기
퍼헥실린PerhexillinePerhexiline USP/EP/BPPerhexiline (Mixture of Diastereomers)(S)-2-(2,2-Dicyclohexylethyl)piperidine(R)-2-(2,2-Dicyclohexylethyl)piperidine(2S)-2-(2,2-Dicyclohexylethyl)piperidine(2R)-2-(2,2-Dicyclohexylethyl)piperidine
C08EX02229-569-5Perhexilinum [INN-Latin]Perhexilina [INN-Spanish](+)-2-(2,2-Dicyclohexylethyl)piperidine(-)-2-(2,2-Dicyclohexylethyl)piperidine39648-48-1Perhexiline (INN)

데이터베이스 식별자

CAS
35193-73-8、39648-47-0、39648-48-1、6621-47-2
PubChem CID
4746
DTXSID
DTXSID7023439
ChEMBL
CHEMBL75880
ChEBI
CHEBI:35553
UNII
KU65374X44
EC Number
229-569-5、252-426-3、254-558-7、254-559-2
Nikkaji
J261.412J、J261.413H、J8.427A

물성

구조 계산 물성

XLogP
6.8
극성 표면적
12 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
1
회전 가능 결합 수
4
무거운 원자 수
20
형식 전하
0
복잡도
245

실험 및 물리화학적 성질

LogP6.2
Solubility2.72e-05 g/L
Physical DescriptionSolid
Collision Cross Section179.09 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

끓는 점
340 · 340.0±10.0 °C(Predicted)
밀도
0.926 · 0.926±0.06 g/cm3(Predicted)
산도 계수 (pKa)
10.36 · pKa 10.36 ± 0.06(40% EtOH,t =25,) (Uncertain)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Exposure RoutesWell absorbed (>80%) from the gastrointestinal tract following oral administration.
Toxicity Summary · 1건

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.

Signs and SymptomsShort term adverse effects include nausea, transient dizziness, hypoglycaemia in diabetic patients, and torsade de pointes (rare).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Perhexiline

vMost-DILI-concern

8

Withdrawn

DOI:10.1016/j.drudis.2016.02.015

Toxicity DataLD50: 2150 mg/kg (Oral, Rat) (A308) LD50: 2641 mg/kg (Oral, Mouse) (A308)

화학 및 산업

약리 정보

ATC Code · 2건

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingPerhexiline and its metabolites are highly protein bound (>90%).
Pharmacodynamics · 1건

Used in the treatment of unresponsive or refractory angina. Perhexiline increases glucose metabolism at the expense of free-fatty-acid metabolism, enhancing oxygen efficiency during myocardial ischaemia. Perhexiline also potentiates platelet responsiveness to nitric oxide both in patients with angina and patients with acute coronary syndrome. The predominant mechanism of this particular perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for nitric oxide clearance by neutrophil-derived oxygen. Perhexiline relieves symptoms of angina, improves exercise tolerance, and increases the workload needed to induce ischaemia when used as monotherapy. The primary therapeutic roles for perhexiline are as short-term therapy (less than 3 months duration) in patients with severe ischaemia awaiting coronary revascularisation or long-term therapy in patients with ischaemic symptoms refractory to other therapeutic measures.

Mechanism of Action · 1건

Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.

Biological Half-LifeVariable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.
Metabolism/Metabolites · 2건

The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6).

관련 반응

2건
반응 기록 만들기
HRID 479328 반응식
HRID 479328반응물로
HRID 2315973 반응식
HRID 2315973생성물로반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

The principal metabolites of perhexiline in man are monohydroxyperhexiline (which is excreted, in part, conjugated with glucuronic acid) and dihydroxyperhexiline that accounts for a relatively small proportion of the total metabolites. Two unidentified metabolites have also been found in the faeces. The pharmacological activity of the metabolites is not known. Hydroxylation of perhexiline is controlled by cytochrome P450 2D6 (CY P450 2D6). Half Life: Variable and non-linear. Some reports show a half-life of 2-6 days, others indicate it could be as high as 30 days.

MeSH Pharmacological Classification · 3건

A class of drugs that act by selective inhibition of calcium influx through cellular membranes.

Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and ExcretionWell absorbed (>80%) from the gastrointestinal tract following oral administration.
Cellular LocationsCytoplasm

용도 및 제조

UsesFor the management of severe angina pectoris.

응용 분야

용도Vasodilator (coronary).

상·하류 제품 정보

상류 원료

염산수산화나트륨수소Cyclohexylmagnesium bromide포름산에틸말레인산